Treatment with anti-TIGIT mAbs resulted in an increased infiltration of active NK-cells into the intratumoral region, a reversion of the exhausted state (measured by increased expression of CD107a, TNF, IFN-γ, and CD226), inhibited tumor growth, reduced tumor metastasis and ultimately increased overall survival of the mice. The gene discussed is CD226; the disease is neoplasm.